Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
autologous cd4+t cells stimulated and expanded ex vivo by a mog peptide modified by the introduction of a thioreductase motif into the flanking residues of the t cell epitope (1 trial)
dimethyl fumarate (tecfidera) (1 trial)
imcy-0098 (3 trials)
imcy-0141 (1 trial)
Diabetes Mellitus (Phase 1)
Diabetes Mellitus, Type 1 (Phase 1)
Multiple Sclerosis (Phase 2)
Multiple Sclerosis, Relapsing-Remitting (Phase 2)
Sclerosis (Phase 2)
Trials (5 total)
Trial APIs (4 total)